Logo

Sylvie Grégoire, James Mullen

Feb 09, 2015

Sylvie Grégoire has been elected to the board of PerkinElmer. She has more than 30 years of industry experience and most recently served for seven years as the president of human genetic therapies at Shire. Prior to that, she was executive chairwoman of IDM Pharma, currently a subsidiary of Takeda Pharmaceuticals. She also has been president and CEO of GlycoFi and held leadership, regulatory, and clinical research positions at Biogen and Merck. Grégoire is currently a board member of Galenica.

The firm also said that James Mullen has decided not to stand for re-election as a director of the company at the annual meeting of shareholders to be held on April 28, 2015.

Breaking News
The Scan

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.

Seagull Microbiome Altered by Microplastic Exposure

The overall diversity and the composition at gut microbiome sites appear to coincide with microplastic exposure and ingestion in two wild bird species, according to a new Nature Ecology and Evolution study.

Study Traces Bladder Cancer Risk Contributors in Organ Transplant Recipients

In eLife, genome and transcriptome sequencing reveal mutation signatures, recurrent somatic mutations, and risky virus sequences in bladder cancers occurring in transplant recipients.

Genes Linked to White-Tailed Jackrabbits' Winter Coat Color Change

Climate change, the researchers noted in Science, may lead to camouflage mismatch and increase predation of white-tailed jackrabbits.